Alcidion Group (ALC.AX) Stock Price

Alcidion Group Price

ASX·CLOSED
0.10
​
Market closed

Revenue has compounded at 55.4% per year over the past 14 years to 51.64 M AUD. Alcidion Group's net margin stands at 4.4%, up from -12.8% several years earlier. Analysts set a median price target of 0.14 AUD, implying 36.0% above the current price. Of 7 analysts, 5 rate the stock a buy — an overall Buy consensus.

Alcidion Group stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alcidion Group business model & stock analysis

Alcidion Group Ltd. generates revenue through the development and licensing of its healthcare software products, including Miya Precision, Miya Observations, Flow, Task Management, and PAS, marketed under the Miya brand. The company also resells selected healthcare software from strategic partners and provides implementation, support, maintenance, and data analysis services to healthcare customers in Australia, New Zealand, and the United Kingdom. Its flagship product Miya Precision, a FHIR-event platform-based solution, supports clinical and operational applications, while Smartpage offers hospital communication and task management via smartphone and web. The firm serves over 400 hospitals across its key markets. Miya Precision and its associated modules form the core of Alcidion's product portfolio, targeting hospitals seeking integrated clinical solutions. Smartpage, Patientrack, and Silverlink PCS complement these offerings, catering to diverse healthcare communication and operational needs. The company’s revenue streams are driven by direct sales of software licenses, ongoing service contracts, and partner resales, with a focus on the Australian, New Zealand, and UK healthcare sectors. Alcidion’s business model emphasizes software licensing and service delivery, with Miya Precision as the primary revenue generator. The company’s strategic partnerships enable it to resell third-party software, expanding its product range without additional development costs. Healthcare institutions in Australia, New Zealand, and the United Kingdom are the primary buyers, leveraging Alcidion’s solutions for improved clinical workflows and operational efficiency.

Frequently asked questions about Alcidion Group

Analysts currently set an average price target of 0.15 AUD for the Alcidion Group stock (median: 0.14 AUD), implying +42.5 % versus the latest price. The consensus is based on 7 analyst ratings.

7 analysts currently rate the Alcidion Group stock: 5 recommend buying, 2 holding and 0 selling.

Converted at the current exchange rate, the Alcidion Group share trades at 0.06 EUR (0.10 AUD).

The Alcidion Group share (ALC.AX) is listed on 1 stock exchanges, including: ASX (ALC.AX).

The revenue of Alcidion Group is 51.64 M AUD. This figure is based on current financial data and reflects the company's business performance.

The profit of Alcidion Group is 2.29 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Alcidion Group is currently 61.72. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Alcidion Group stock.

The price-to-sales ratio (P/S) of Alcidion Group is currently 2.73. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Alcidion Group stock.

The Eulerpool Quality Score for Alcidion Group is 5/10.

The ISIN of Alcidion Group is AU000000ALC6. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Alcidion Group is ALC.AX. The ticker symbol is used to trade Alcidion Group shares on the stock exchange.

Fair ValueTerminal
0.09 AUD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Technology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website alcidion.com
Country
Australia
Currency
AUD
Initial public offering
Jun 24, 2011
ISIN
AU000000ALC6
Cusip
Q65004139
Market capitalization
141.00 M AUDMicro Cap
52-Week Range
PEG
1.72
P/E ratio
P/Ee 2027
49.27
P/Ee 2028
31.55
P/Ee 2029
19.66
P/S
P/Se
2.72
EV/EBIT
47.48
P/B Ratio
1.55
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
2.49 %
Last updated Nov 11, 2026, 3:38 AM

Alcidion Group Peer Group

Alcidion Group Ticker

ASX · ALC.AX

Alcidion Group FIGI

ALC:AU · BBG001P0XB53ALC:AT · BBG001P0XB62ALC:AH · BBG002F3T5N4